Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage

Abstract

The aim of the present study was to assess the therapeutic effects of atorvastatin on cerebral vessel autoregulation and to explore the underlying mechanisms in a rabbit model of subarachnoid hemorrhage (SAH). A total of 48 healthy male New Zealand rabbits (weight, 2–2.5 kg) were randomly allocated into SAH, Sham or SAH + atorvastatin groups (n=16/group). The Sham group received 20 mg/kg/d saline solution, whereas 20 mg/kg/d atorvastatin was administered to rabbits in the SAH + atorvastatin group following SAH induction. Changes in diameter, perimeter and basilar artery (BA) area were assessed and expression levels of the vasoactive molecules endothelin-1 (ET-1), von Willebrand factor (vWF) and thrombomodulin (TM) were measured. Neuronal apoptosis was analyzed 72 h following SAH by terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling (TUNEL) staining. The mortality rate in the SAH group was 18.75, 25% in the SAH + atorvastatin treated group and 0% in the Sham group (n=16/group). The neurological score in the SAH + atorvastatin group was 1.75±0.68, which was significantly higher compared with the Sham group (0.38±0.49; P<0.05). The BA area in the SAH + atorvastatin group (89.6±9.11) was significantly lower compared with the SAH group (115.4±11.0; P<0.01). The present study demonstrated that SAH induction resulted in a significant increase in the diameter, perimeter and cross-sectional area of the BA in the SAH + atorvastatin group. Administration of atorvastatin may significantly downregulate the expression levels of ET-1, vWF and TM (all P<0.01) vs. sham and SAH groups. TUNEL staining demonstrated that neuronal apoptosis was remarkably reduced in the hippocampus of SAH rabbits following treatment with atorvastatin (P<0.05). Atorvastatin treatment may alleviate cerebral vasospasm and mediate structural and functional remodeling of vascular endothelial cells, in addition to promoting anti-apoptotic signaling. These results provided supporting evidence for the use of atorvastatin as an effective and well-tolerated treatment for SAH in various clinical settings and may protect the autoregulation of cerebral vessels.

The Potential Value of Targeting Ferroptosis in Early Brain Injury After Acute CNS Disease

“…Each process consumes energy and is regulated by cell signaling pathways, which is the basis for this type of death being called programmed cell death. However, none of these mechanisms fully explain the early brain damage caused by acute CNS disease (Chen et al, 2016(Chen et al, , 2018Zille et al, 2017).…”

Effects of Perioperative Rosuvastatin for Postoperative Delirium After Elderly General Anesthesia Patients: A Randomized, Double-Blind, and Placebo-Controlled Trial

“…Statins can reduce the concentration of glutamate by upregulation of nitric oxide synthase, and Jiang [28] also found that statins can inhibit 5-HT and 5-HTT expression in chronic obstructive pulmonary disease and pulmonary artery hypertension, then it may be ameliorated delirium by regulating neurotransmitters. Many previous studies indicated that statins can alleviate cerebral vasospasm, cerebral perfusion, prevents endothelial dysfunction, and ameliorating neuronal apoptosis and brain injury [7,9,10].…”

“…Statins, as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, are widely used in cardiovascular disorders as cholesterol-lowering medications. Recent studies had indicated that statins have been proven to exert pleiotropic effects, including anti-inflammatory, antioxidative stress, inhibit platelet aggregation, and neuroprotection [7][8][9][10]. As the neuroprotection related molecular mechanism was similar to the delirium, so it indicated that statins may prevent delirium.…”

Controlled Decompression Attenuates Brain Injury in a Novel Rabbit Model of Acute Intracranial Hypertension

“…After conservative treatment fails to control refractory intracranial hypertension (e.g., ICP >25 mmHg for a long period of time), there is sufficient evidence to support the use of decompression as a life-saving intervention [17]. Rapid decompressive craniectomy can reduce ICP, thus improving cerebrovascular compliance [18], cerebral oxygenation [19,20], and cerebral perfusion [21,22], and can also reduce postoperative brain edema [11], but it also leads to a high probability of rebleeding and brain swelling during surgery or post-operatively. Flint et al reported that 58% of patients (n=40) experienced acute encephalocele and ipsilateral or contralateral rebleeding with rapid decompressive craniectomy [23], which sharply increases ICP and aggravates cytotoxicity and angiogenic brain edema [24,25].…”

“…Behavioral scores were recorded by an evaluator who did not participate in the experiment. A scoring table was used to assess neural function at 24 h after the operation [10,11]. The behavioral study included the following 3 tests: I) Appetite.…”